PFIZER INC Finite-Lived Intangible Asset, Expected Amortization, Year One
PFIZER INC (PFE) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $4.68 billion as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.68B.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.84B.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $5.08B.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.22B.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $4.68B 10-K · filed 2026-02-26 |
| 2024-12-31 | $4.84B 10-K · filed 2025-02-27 |
| 2023-12-31 | $5.08B 10-K · filed 2024-02-22 |
| 2022-12-31 | $4.22B 10-K · filed 2023-02-23 |
| 2021-12-31 | $3.28B 10-K · filed 2022-02-24 |
| 2020-12-31 | $3.37B 10-K · filed 2021-02-25 |
| 2019-12-31 | $3.48B 10-K · filed 2020-02-27 |
| 2018-12-31 | $4.58B 10-K · filed 2019-02-28 |
| 2017-12-31 | $4.80B 10-K · filed 2018-02-22 |
| 2016-12-31 | $4.83B 10-K · filed 2017-02-23 |
| 2015-12-31 | $3.88B 10-K · filed 2016-02-29 |
| 2014-12-31 | $3.67B 10-K · filed 2015-02-27 |
| 2013-12-31 | $4.10B 10-K · filed 2014-02-28 |
| 2012-12-31 | $4.80B 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |